Osteoporosis and cardiovascular disease are the potential consequences of shared mechanisms.

Anti-osteoporosis medications are associated with potential increases in cardiac risk (romosozumab, calcium supplementation, menopausal hormonal therapy), no effect on cardiac risk (vitamin D) or reduced cardiac risk (bisphosphonates).

Selective estrogen receptor modulators, such as raloxifene, and menopausal hormonal therapy are associated with increased risk of venous thromboembolic disease.

Romosozumab therapy is contra-indicated in those with a history of myocardial infarction or ischaemic stroke.